02105 來凱醫藥－Ｂ
LAEKNA-B
LAEKNA-B
| Listing Date | 2023/06/29 |
| Listing Price | 12.410 |
Quote
Subscription Result
- Subscription Rate5.81x
- Guarantee One Lot Size5 lot
- One Lot Success Rate22.31%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Laekna, Inc. founded in 2016, it is a clinical-stage biotechnology company. It has two Core Products and 14 other pipeline product candidates.
--
Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The other Core Product LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer.
--
The Group have initiated one registrational clinical trial and another five clinical trials for Core Products LAE002 and LAE001. As of 6 June 2023, it owned 176 patents and patent applications including in-licensed patents and patent applications with global rights.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 63.73M shares |
| No. of International Offer Shares | 57.36M shares |
| No. of HK Offer Shares | 6.37M shares |
| Offer Price | $12.41 |
| Stock Code | 2105 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, Haitong International Securities Company Limited, ICBC International Securities Limited, Guotai Junan Securities (Hong Kong) Limited, ABCI Securities Company Limited, Futu Securities International (Hong Kong) Limited, Valuable Capital Limited |
TIME TABLE
| Application Period | Jun 16 (Fri) - noon, Jun 21 (Wed) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jun 28 (Wed) |
| Result Announcement Date | On or before Jun 28 (Wed) |
| Result Announcement Date | On or before Jun 28 (Wed) |
| Dealings in Shares commence on | Jun 29, 2023. (Thu) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $12.41 |
| Capitalization | 4.84B |
| NAV / share ($) | $2.83 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 12.41, the net proceeds raised would be HKD 708.20M, of which |
| 33% : Advancing the clinical development and approval of one of Core Products LAE001 |
| 23.3% : Advancing the clinical development and approval of the other Core Product of the Company, LAE002 |
| 20.8% : Accelerating the research and development of other existing pipeline products |
| 9.9% : Improving production capabilities and developing manufacturing capacities |
| 7.6% : Business development activities and enhancing global reach |
| 5.4% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).